Screener
Ultragenyx Pharmaceutical RARE Retained Earnings
Retained Earnings at other companies
Other financials
Where this comes from
Reported directly by Ultragenyx Pharmaceutical in its filing.
Tagged under the XBRL concept us-gaap:RetainedEarningsAccumulatedDeficit.
The source filing: Ultragenyx Pharmaceutical’s 10-Q, filed August 5, 2026. Open the filing →
- Filed
- Aug 4, 2026, 8:00 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-333233
FAQ
- What is Ultragenyx Pharmaceutical's retained earnings?
- Ultragenyx Pharmaceutical (RARE) reported retained earnings of -$4.81B in Q2 2026.
- How has Ultragenyx Pharmaceutical's retained earnings changed year-over-year?
- Ultragenyx Pharmaceutical's retained earnings decreased by 13.9% year-over-year, from -$4.22B to -$4.81B.
- What is the long-term trend for Ultragenyx Pharmaceutical's retained earnings?
- Over 5 years (2020 to 2025), Ultragenyx Pharmaceutical's retained earnings has grown at a 22.9% compound annual growth rate (CAGR), from -$1.62B to -$4.53B.
- What does retained earnings mean?
- Cumulative net income earned since inception minus all dividends paid — the total profits reinvested in the business over its lifetime.
Ask your AI about Ultragenyx Pharmaceutical's retained earnings.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude